Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
12 June 2020Next earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:47:45 GMTDividend
Analysts recommendations
Institutional Ownership
RNA Latest News
The company's most promising pipeline program can continue unabated.
SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: Chardan 8th Annual Genetic Medicines Conference on October 1 at 7:30 a.m.
Goldman Sachs has initiated coverage on Avidity Biosciences Inc RNA based on multi-blockbuster, first-to-market commercial opportunities for its investigational candidates.
SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: Wells Fargo 2024 Healthcare Conference on September 4 at 5:00 a.m. PT / 8:00 a.m.
SAN DIEGO , Aug. 19, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 8,418,000 shares of its common stock, including 1,098,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $41.00 per share. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $345.1 million.
However, even with this massive appreciation, Wall Street analysts still see a solid upside in the stock. Based on recent analyst changes, the average price target is $62, implying an upside of 39%.
SAN DIEGO , Aug. 14, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its upsized underwritten public offering of 7,320,000 shares of its common stock at a price to the public of $41.00 per share. All of the shares to be sold in the offering are to be sold by Avidity.
SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock.
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.66 per share a year ago.
Avidity reports positive del-zota (AOC 1044) data; demonstrated 25% increase in dystrophin production and reduction of creatine kinase levels to near normal in people living with DMD44 in Phase 1/2 EXPLORE44™ trial Initiated global Phase 3 HARBOR™ trial and began administration of del-desiran in people living with DM1; del-desiran received FDA Breakthrough Therapy designation Avidity plans to accelerate initiation of del-brax (AOC 1020) registrational cohorts after reporting unprecedented and consistent reductions in DUX4 regulated genes, trends of functional improvement and favorable safety and tolerability in people living with FSHD in Phase 1/2 FORTITUDE™ trial Announcement of our lead precision cardiology program target planned for Q4 2024 Cash on hand of approximately $1.3 billion SAN DIEGO , Aug. 9, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "The last few months have been incredible for Avidity, but more importantly, for people living with DM1, FSHD and DMD.
- 1(current)
What type of business is Avidity Biosciences?
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
What sector is Avidity Biosciences in?
Avidity Biosciences is in the Healthcare sector
What industry is Avidity Biosciences in?
Avidity Biosciences is in the Biotechnology industry
What country is Avidity Biosciences from?
Avidity Biosciences is headquartered in United States
When did Avidity Biosciences go public?
Avidity Biosciences initial public offering (IPO) was on 12 June 2020
What is Avidity Biosciences website?
https://www.aviditybiosciences.com
Is Avidity Biosciences in the S&P 500?
No, Avidity Biosciences is not included in the S&P 500 index
Is Avidity Biosciences in the NASDAQ 100?
No, Avidity Biosciences is not included in the NASDAQ 100 index
Is Avidity Biosciences in the Dow Jones?
No, Avidity Biosciences is not included in the Dow Jones index
When was Avidity Biosciences the previous earnings report?
No data
When does Avidity Biosciences earnings report?
The next expected earnings date for Avidity Biosciences is 08 November 2024